VEA
ALXO icon

Virtus ETF Advisers’s ALX Oncology ALXO Stock Holding History

Virtus ETF Advisers’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,920
Closed -$19.9K – 467
2024
Q3 		$19.9K Buy
10,920
+194
+2% +$721 0.01% 451
2024
Q2 		$64.7K Buy
10,726
+4,160
+63% +$51.2K 0.03% 439
2024
Q1 		$73.2K Sell
6,566
-453
-6% -$6.36K 0.04% 404
2023
Q4 		$105K Sell
7,019
-3,708
-35% -$35.2K 0.07% 340
2023
Q3 		$51.5K Sell
10,727
-1,067
-9% -$5.79K 0.03% 414
2023
Q2 		$88.6K Buy
11,794
+2,775
+31% +$18.2K 0.05% 418
2023
Q1 		$40.8K Sell
9,019
-3,465
-28% -$26.3K 0.02% 435
2022
Q4 		$141K Sell
12,484
-3,272
-21% -$36.8K 0.07% 364
2022
Q3 		$151K Buy
15,756
+115
+0.7% +$1.34K 0.06% 353
2022
Q2 		$127K Buy
15,641
+9,176
+142% +$99.9K 0.05% 362
2022
Q1 		$109K Sell
6,465
-379
-6% -$6.47K 0.05% 289
2021
Q4 		$147K Buy
6,844
+3,318
+94% +$143K 0.06% 354
2021
Q3 		$260K Sell
3,526
-192
-5% -$12.8K 0.11% 214
2021
Q2 		$203K Sell
3,718
-40
-1% -$2.39K 0.08% 333
2021
Q1 		$277K Buy
3,758
+70
+2% +$5.51K 0.12% 258
2020
Q4 		$318K Buy
+3,688
New +$222K 0.13% 194

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return

Virtus ETF Advisers's ALXO Position: Q4 2024 in Review

Virtus ETF Advisers sold out of ALX Oncology (ALXO) in Q4 2024, closing a stake of 10,920 shares — an estimated $19.9K sold.

Virtus ETF Advisers first reported a position in ALXO in Q4 2020 and held it in 16 quarters. The position peaked at $318K in Q4 2020. 87 funds tracked by Wall St. Rank hold ALXO as of Q4 2024.

  • Virtus ETF Advisers reported no remaining ALX Oncology position as of Q4 2024 after selling out during the quarter.
  • Virtus ETF Advisers sold 10,920 ALX Oncology shares in Q4 2024, an estimated $19.9K.
  • Virtus ETF Advisers first reported a position in ALX Oncology in Q4 2020 and held it in 16 quarters.
  • Virtus ETF Advisers's ALX Oncology position peaked at $318K in Q4 2020.
  • 87 funds tracked by Wall St. Rank held ALX Oncology as of Q4 2024.

Based on Virtus ETF Advisers's 13F filing for Q4 2024, filed 14 Feb 2025.